Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva pharma - produtos farmacêuticos, lda. - mefloquina - comprimido revestido - 250 mg - mefloquina, cloridrato 275 mg - mefloquine - n/a - duração do tratamento: longa duração

Den europeiske union - engelsk - EMA (European Medicines Agency)

jenson pharmaceutical services limited - dextromethorphan, quinidine - neurobehavioral manifestations - other nervous system drugs - nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (pba) in adults. efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.

Israel - engelsk - Ministry of Health

teva pharmaceutical industries ltd, israel - valproic acid - capsules - valproic acid 200 mg - valproic acid - valproic acid - sole or adjunctive therapy in the treatment of simple (petit mal) and complex absence seizures. may also be used adjunctively in patients with multiple seizure types which include absence seizures.

Israel - engelsk - Ministry of Health

teva pharmaceutical industries ltd, israel - valproic acid - capsules - valproic acid 200 mg - valproic acid - valproic acid - sole or adjunctive therapy in the treatment of simple (petit mal) and complex absence seizures. may also be used adjunctively in patients with multiple seizure types which include absence seizures.

Israel - engelsk - Ministry of Health

teva pharmaceutical industries ltd, israel - valproic acid as sodium - syrup - valproic acid as sodium 200 mg / 5 ml - valproic acid - valproic acid - sole or adjunctive therapy in the treatment of simple (petit mal) and complex absence seizures. valporal may also be used adjunctively in patients with multiple seizure types which include absence seizures.

Israel - engelsk - Ministry of Health

glaxo smith kline (israel) ltd - atovaquone; proguanil hydrochloride - film coated tablets - atovaquone 62.5 mg; proguanil hydrochloride 25 mg - proguanil, combinations - proguanil, combinations - "- prevention of malaria:for the prophylaxis of p.falciparum malaria, including in areas where chloroquine resistance has been reported.- treatment of malaria: for the treatment of acute, uncomplicated p.flaciparum malaria.malarone has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance.

Israel - engelsk - Ministry of Health

glaxo smith kline (israel) ltd - atovaquone; proguanil hydrochloride - film coated tablets - atovaquone 250 mg; proguanil hydrochloride 100 mg - proguanil, combinations - proguanil, combinations - prevention of malaria: for the prophylaxis of p.falciparum malaria, including in areas where chloroquine resistance has been reported. treatment of malaria: for the treatment of acute, uncomplicated p.flaciparum malaria. malarone has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance.

USA - engelsk - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - quinine sulfate (unii: kf7z0e0q2b) (quinine - unii:a7v27phc7a) - quinine sulfate 324 mg - qualaquin is an antimalarial drug indicated only for treatment of uncomplicated plasmodium falciparum malaria. quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [see clinical studies (14) ]. limitations of use: qualaquin is not approved for: qualaquin is contraindicated in patients with the following: risk summary prolonged experience with quinine in pregnant women over several decades, based on published prospective and retrospective observational studies, surveys, safety and efficacy studies, review articles, case reports and case series have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes (see data) . in animal reproduction studies, administration of quinine by multiple routes of administration to pregnant rabbits, dogs, guinea pigs, rats, and monkeys during the period of organogenesis at doses of 0.25 to 2 times the maximum recommended human dose (mrhd) based on body su

USA - engelsk - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - quinine sulfate (unii: kf7z0e0q2b) (quinine - unii:a7v27phc7a) - quinine sulfate 324 mg - quinine sulfate capsules are an antimalarial drug indicated only for treatment of uncomplicated plasmodium falciparum malaria. quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [see clinical studies (14) ]. limitations of use: quinine sulfate capsules are not approved for: - treatment of severe or complicated p. falciparum malaria. - prevention of malaria. - treatment or prevention of nocturnal leg cramps [see warnings and precautions (5.1) ]. quinine sulfate capsules are contraindicated in patients with the following: - prolonged qt interval. one case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged qt interval at baseline, who received quinine sulfate intravenously for p. falciparum malaria [see warnings and precautions (5.4) ]. - known hypersensitivity reactions to quinine. these include, but are not limited to, the following [see warnings and precautions (5.7) ]: thrombocytopenia idiopathic

Den europeiske union - fransk - EMA (European Medicines Agency)

jenson pharmaceutical services limited - le dextrométhorphane, la quinidine - manifestations neurocomportementales - autres médicaments du système nerveux - nuedexta est indiqué pour le traitement symptomatique de l'affect pseudobulbaire chez les adultes. efficacité a seulement été étudiée chez les patients atteints de sclérose latérale amyotrophique ou sclérose sous-jacente.